Record customer growth and expanded US capacity drove a 10% currency-adjusted sales increase, with strong momentum in spine and dental segments. Despite negative earnings, the company targets over 25% annual growth and a 40% EBITDA margin, reinvesting profits for future expansion.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.